 |
|
|
| |
A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study
|
| |
| |
Reported by Jules Levin
APASL - Asian Pacific Association for The Study of the Liver
March 12-15 2014
Brisbane, Australia
Reddy KR,1 Zeuzem S,2 Zoulim F,3 Weiland O,4 Horban A,5 Stanciu C,6 Villamil F,7 Andreone P,8 George J,9 Dammers E,10 Fu M,11 Kurland D,12 Lenz O,10 Ouwerkerk-Mahadevan S,13 Verbinnen T,10 Jessner W10
1Division of Gastroenterology and Hepatology, University of Pennsylvania, PA, USA; 2Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany; 3Hopital de la Croix Rousse, Lyon, France; 4Karolinska University Hospital, Huddinge, Stockholm, Sweden; 5Wojewodzki Szpital Zakazny, Warsaw, Poland; 6Gastromedica Clinic, University Hospital St Spiridon, Iasi, Romania; 7CIPREC, Buenos Aires, Argentina; 8Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy; 9Westmead Hospital and Westmead Millennium Institute for Medical Research, Westmead, New South Wales, Australia; 10Janssen Infectious Diseases BVBA, Beerse, Belgium; 11Janssen Research & Development, Spring House, PA, USA; 12Janssen Research & Development, Titusville, NJ, USA; 13Janssen Research & Development, Beerse, Belgium
|
| |
|
|
|
|
|
